Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Folfox Protocol Clear all
Recruiting Phase 1 Interventional

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

NCT06719362
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen
Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions
BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions
MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Drug · Combination Product
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
31
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis

NCT00352755
View directory record Official record
Conditions
Peritoneal Neoplasms
Interventions
Surgical debulking with peritonectomy, Intraperitoneal 5FU, FOLFOX
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

NCT00384176
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX), Leucovorin (in FOLFOX), Oxaliplatin (in FOLFOX)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Casa Grande, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

NCT01581307
View directory record Official record
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Results available

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

NCT03250832
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00381706
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, ECF, IC, FOLFOX
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
227
States / cities
Norwalk, Connecticut • Lewes, Delaware • Newark, Delaware + 158 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 20, 2026, 5:38 PM EDT
Withdrawn Phase 2 Interventional

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

NCT01270438
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Not applicable Interventional

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

NCT05526079
View directory record Official record
Conditions
Rectal Cancer
Interventions
Watchfuf waiting
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324
View directory record Official record
Conditions
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Interventions
INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab, ADG126
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional

Organ Preservation in Early Rectal Cancer Patients

NCT03548961
View directory record Official record
Conditions
Rectal Cancer
Interventions
FOLFOX regimen
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 3 Interventional

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

NCT07265674
View directory record Official record
Conditions
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Interventions
Nanvuranlat, Physician's Best Choice
Drug · Other
Lead sponsor
J-Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Duarte, California • Orange, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer

NCT03781323
View directory record Official record
Conditions
Advanced Rectal Cancer
Interventions
FOLFOX
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 3 Interventional

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Phase 2 Interventional

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

NCT04587128
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

NCT03861702
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma(LAPC)
Interventions
FOLFOX regimen, Liposomal Irinotecan
Drug
Lead sponsor
Nelson Yee
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

NCT07500298
View directory record Official record
Conditions
Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
Interventions
SAR445877, FOLFOX6, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

NCT00479583
View directory record Official record
Conditions
Cancer
Interventions
BMS-690514 / FOLFIRI, BMS-690514 / FOLFOX
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Chemoradiation or Brachytherapy for Rectal Cancer

NCT02017704
View directory record Official record
Conditions
Rectal Cancer
Interventions
Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), IMRT (intensity modulated radiation therapy), FOLFOX6, Surgery
Radiation · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer

NCT00059930
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFOX regimen, dexamethasone, floxuridine, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

NCT03662659
View directory record Official record
Conditions
Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction
Interventions
BMS-986213, Nivolumab, XELOX, FOLFOX, SOX
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
13
States / cities
Clovis, California • Duarte, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

NCT01363843
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
FOLFOX6, RT with concurrent chemotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
William Sikov MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Pawtucket, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 20, 2026, 5:38 PM EDT